Patent ID: 6861437

Claim:
A method of treatment or prevention of a mGluR5 receptor mediated disease comprising administering, to a person in need of such treatment, a therapeutically effective amount of a compound of formula wherein R 1 is selected from the group consisting of hydrogen, (C 1-6 )-alkyl, halogen, hydroxy and R 2 is selected from the group consisting of hydrogen, (C 1-6 )-alkyl, halogen, hydroxy and (C 1-6 )-alkoxy; A is unsubstituted aryl or aryl substituted with at least one substituent selected from the group consisting of (C 1-6 )-alkyl, halogen, halogen-(C 1-6 )-alkyl, hydroxy, (C 1-6 )-alkoxy, benzyloxy, amino, (C 1-6 )-alkylamino, di-(C 1-6 )-alkyl-amino, arylamino, diarylamino and nitro, or is unsubstituted heteroaryl or heteroaryl substituted with at least one substituent selected from the group consisting of(C 1-6 )-alkyl, halogen, halogen-(C 1-6 )-alkyl, hydroxy, (C 1-6 )-alkoxy, benzyloxy, amino, (C 1-6 )-alkylamino, di-(C 1-6 )-alkyl-amino, arylamino, diarylamino and nitro, or is the group wherein X a and X b are, independently from each other, selected from the group consisting of —CH 2 — and —O—; and n is 1 or 2; or a pharmaceutically acceptable salt thereof.